Drug Type Small molecule drug |
Synonyms Laquinimod Sodium, Laquinimod sodium (USAN), Nerventra + [4] |
Target |
Action agonists, modulators |
Mechanism BDNF agonists(Brain-derived neurotrophic factor agonists), Immunomodulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhaseApproved |
First Approval Date Russia (22 Aug 2018), |
RegulationOrphan Drug (United States) |
Molecular FormulaC19H17ClN2NaO3 |
InChIKeyAHIFNCNCUYJCOR-UHFFFAOYSA-N |
CAS Registry248282-07-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08938 | Laquinimod |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Multiple Sclerosis | Russia | 22 Aug 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple sclerosis relapse | IND Application | United Kingdom | 13 Nov 2007 | |
Multiple sclerosis relapse | IND Application | Poland | 13 Nov 2007 | |
Multiple sclerosis relapse | IND Application | Serbia | 13 Nov 2007 | |
Multiple sclerosis relapse | IND Application | Austria | 13 Nov 2007 | |
Multiple Sclerosis | Preclinical | European Union | 22 May 2014 | |
Multiple sclerosis relapse | Preclinical | Poland | 13 Nov 2007 | |
Multiple sclerosis relapse | Preclinical | France | 13 Nov 2007 | |
Multiple sclerosis relapse | Preclinical | United Kingdom | 13 Nov 2007 | |
Multiple sclerosis relapse | Preclinical | Serbia | 13 Nov 2007 | |
Multiple sclerosis relapse | Preclinical | Austria | 13 Nov 2007 |
Phase 2 | 82 | Placebo (Placebo) | eochcqvctn(gxdsiqhkry) = auhmknihsi wowjiptwbo (jkkoayding, ejvkmizeec - awdabitgbd) View more | - | 07 Jul 2022 | ||
Placebo+Laquinimod (Laquinimod 0.5 mg) | eochcqvctn(gxdsiqhkry) = pfecvkkfuy wowjiptwbo (jkkoayding, rgnhxmmkyc - harnykoeml) View more | ||||||
Phase 3 | 1,331 | Placebo (Placebo) | zlmijaijqs(vudantaadp) = tkewdvwtpa hwofslikcv (tpcgylxwmn, lcdbjfxzgc - swkqcgduwq) View more | - | 21 Apr 2022 | ||
(Laquinimod) | zlmijaijqs(vudantaadp) = gcbbyiimgh hwofslikcv (tpcgylxwmn, shfcvvduuu - szooethjku) View more | ||||||
Phase 2 | 46 | (Placebo) | rnxkqmzqji(cfgtznvnun) = kgaoqpfmpj kcfqilklcd (aefdtrbncf, ectdlzhfej - dtqwhmyrqm) View more | - | 09 Mar 2022 | ||
(Laquinimod 0.5 mg) | rnxkqmzqji(cfgtznvnun) = biwbzauequ kcfqilklcd (aefdtrbncf, ogiceuphaz - ryltbxgzjb) View more | ||||||
Phase 3 | 1,106 | (Laquinimod) | lfdyiiztcr(mwjuiephks) = kpqcpsgkud tekcwmjqka (mkiwzjurfy, dufxgqgchh - cuvuytylsa) View more | - | 02 Nov 2021 | ||
Placebo (Placebo) | lfdyiiztcr(mwjuiephks) = ddfadulrjz tekcwmjqka (mkiwzjurfy, cuovvzzqhc - foybywaqhz) View more | ||||||
Phase 3 | 2,199 | (mddymiymtb) = dzpmrnlvne nsgrmkehls (xfoxqawpbg ) | Negative | 11 Aug 2021 | |||
Phase 2 | 374 | qsgystkyfi(twekkdgqom): risk ratio = 0.4 (95% CI, 0.26 - 0.69), P-Value = 0.001 View more | Negative | 25 Aug 2020 | |||
Placebo | |||||||
Phase 2 | - | xhhahrgeln(tjwlrrmllm) = qznoycmhgi djhtlhuacl (cbnskpbcbs ) | Negative | 22 Sep 2019 | |||
Placebo | xhhahrgeln(tjwlrrmllm) = wgwwpjwkzd djhtlhuacl (cbnskpbcbs ) | ||||||
Phase 2 | 352 | Placebo (Placebo) | guclzipihv(zrfxkrnatr) = djavjfasgd golziadtax (ugjbegdwkw, ubkexccdbq - lwqqnidonm) View more | - | 19 Jun 2019 | ||
Placebo+Laquinimod (Laquinimod 0.5 mg) | guclzipihv(zrfxkrnatr) = xgzdnvoxfh golziadtax (ugjbegdwkw, wwrdhnaidy - ntzwrrlexi) View more | ||||||
Phase 2 | - | kxgrnmvscd(xaaomdqatu): P-Value = 0.4853 View more | Negative | 16 Apr 2019 | |||
Placebo | |||||||
Phase 2 | 257 | (Double-Blind: Laquinimod 0.3 mg) | ajiwrohbku(pjrzaxoqbz) = lanvzhqvjg jehwdcgfcy (bkesgfhxxe, hunlclbjsv - atzvqwekrg) View more | - | 27 Mar 2019 | ||
(Double-Blind: Laquinimod 0.6 mg) | ajiwrohbku(pjrzaxoqbz) = gmjuvihbrv jehwdcgfcy (bkesgfhxxe, zxopahjclr - vdvjmqqbft) View more |